Many potential clinical indications have been identified for integrin antagonists. Integrins are cell adhesion molecules that are involved in numerous biochemical events. Specific integrins have now been identified for specific interactions. By directing antibodies against these molecules, researchers are opening up a whole new field of therapy. The majority of this research is still at the preclinical stage. However, some agents are now approaching clinical trials, as described at the 4th IBC conference on Cell Adhesion Molecules [San Francisco, US; May 1995].